LungLifeAI Logo

LungLife AI - Notice of Results & Investor Presentation

September 3, 2021

3 September 2021

LungLife AI, Inc.
(the “Company” or “LungLife”)

Notice of Results

Investor Presentation

LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer enhanced by artificial intelligence, announces that its maiden unaudited half-year report for the six months ended 30 June 2021 will be announced on Thursday 9 September 2021.

Investor presentation

Paul Pagano, Chief Executive Officer, and David Anderson, Chief Financial Officer, will be hosting a live online presentation relating to the half-year report via the Investor Meet Company platform at 4.30pm (BST) on Thursday 9 September 2021. The presentation is open to all existing and potential shareholders.

Investors can sign up to Investor Meet Company for free and register for the presentation here:

https://www.investormeetcompany.com/lunglife-ai-inc/register-investor

Investors who already follow LungLife on the Investor Meet Company platform will automatically be invited.

Questions can be submitted pre-event via your IMC dashboard or in real time during the presentation, via the "Ask a Question" function.  Whilst the Company may not be in a position to answer every question it receives, it will address the most prominent within the confines of information already disclosed to the market through regulatory notifications. A recording of the presentation, a PDF of the slides used, and responses to the Q&A session will be available on the Investor Meet Company platform afterwards.

Click here to read the full announcement.

Recent News

Operational update
 Block Listing Six Monthly Return 
 Directorate Change 

Subscribe for Email Alerts

"*" indicates required fields

This field is for validation purposes and should be left unchanged.

LungLifeAI Logo
LungLife AI licensure/accreditation information posted here.
© 2023 LungLIfe AI, Inc.
All rights reserved. LiquidBiopsy is a trademark of LungLife AI, Inc.
chevron-down